BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38548353)

  • 1. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [
    Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
    J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
    Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
    Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Epidermal Growth Factor Receptor 2-Targeting [
    Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
    J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
    Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
    Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
    J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
    Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
    J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of
    Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of a
    Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
    Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
    Tolmachev V; Velikyan I; Sandström M; Orlova A
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1356-67. PubMed ID: 20130858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer.
    Alhuseinalkhudhur A; Lubberink M; Lindman H; Tolmachev V; Frejd FY; Feldwisch J; Velikyan I; Sörensen J
    EJNMMI Res; 2020 Mar; 10(1):21. PubMed ID: 32201920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Uptake of
    Mortimer JE; Bading JR; Park JM; Frankel PH; Carroll MI; Tran TT; Poku EK; Rockne RC; Raubitschek AA; Shively JE; Colcher DM
    J Nucl Med; 2018 Jan; 59(1):38-43. PubMed ID: 28637802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of
    Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L
    J Med Imaging Radiat Oncol; 2022 Sep; 66(6):731-737. PubMed ID: 34676675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.